TY - JOUR
T1 - Cognitive disorders in patients with chronic kidney disease
T2 - specificities of clinical assessment
AU - CONNECT Action (Cognitive Decline in Nephro-Neurology European Cooperative Target)
AU - Pépin, Marion
AU - Ferreira, Ana Carina
AU - Arici, Mustafa
AU - Bachman, Maie
AU - Barbieri, Michelangela
AU - Bumblyte, Inga Arune
AU - Carriazo, Sol
AU - Delgado, Pilar
AU - Garneata, Liliana
AU - Giannakou, Konstantinos
AU - Godefroy, Olivier
AU - Grodzicki, Tomasz
AU - Klimkowicz-Mrowiec, Aleksandra
AU - Kurganaite, Justina
AU - Liabeuf, Sophie
AU - Mocanu, Carmen Antonia
AU - Paolisso, Giuseppe
AU - Spasovski, Goce
AU - Vazelov, Evgueniy Stefanov
AU - Viggiano, Davide
AU - Zoccali, Carmine
AU - Massy, Ziad A.
AU - WieRcek, Andrzej
AU - Capasso, Giovambattista
AU - Andrade, Alexandre
AU - Bachmann, Maie
AU - Bumblyte, Inga
AU - Covic, Adrian Constantin
AU - Delgado, Pilar
AU - Endlich, Nicole
AU - Engvig, Andreas
AU - Fouque, Denis
AU - Franssen, Casper
AU - Frische, Sebastian
AU - Garneata, Liliana
AU - Gesualdo, Loreto
AU - Giannakou, Konstantinos
AU - Goumenos, Dimitrios
AU - Kartal, Ayşe Tuğba
AU - Mani, Laila Yasmin
AU - Marti, Hans Peter
AU - Mayer, Christopher
AU - Nielsen, Rikke
AU - Pšić, Vesna
AU - Rroji, Merita
AU - Sakkas, Giorgos
AU - Spasovski, Goce
AU - Stevens, Kate I.
AU - Vazelov, Evgueniy
AU - Zacharia, Lefteris
N1 - Funding Information:
This article is published as part of a supplement financially supported by the COST Action CA19127-Cognitive Decline in Nephro-Neurology: European Cooperative Target (CONNECT).
Publisher Copyright:
© The Author(s) 2021. Published by Oxford University Press on behalf of ERA.
PY - 2022/12/28
Y1 - 2022/12/28
N2 - Neurocognitive disorders are frequent among chronic kidney disease (CKD) patients. Identifying and characterizing cognitive impairment (CI) can help to assess the ability of adherence to CKD risk reduction strategy, identify potentially reversible causes of cognitive decline, modify pharmacotherapy, educate the patient and caregiver and provide appropriate patient and caregiver support. Numerous factors are associated with the development and progression of CI in CKD patients and various conditions can influence the results of cognitive assessment in these patients. Here we review clinical warning signs that should lead to cognitive screening; conditions frequent in CKD at risk to interfere with cognitive testing or performance, including specificities of cognitive assessment in dialysis patients or after kidney transplantation; and available tests for screening and observed cognitive patterns in CKD patients.
AB - Neurocognitive disorders are frequent among chronic kidney disease (CKD) patients. Identifying and characterizing cognitive impairment (CI) can help to assess the ability of adherence to CKD risk reduction strategy, identify potentially reversible causes of cognitive decline, modify pharmacotherapy, educate the patient and caregiver and provide appropriate patient and caregiver support. Numerous factors are associated with the development and progression of CI in CKD patients and various conditions can influence the results of cognitive assessment in these patients. Here we review clinical warning signs that should lead to cognitive screening; conditions frequent in CKD at risk to interfere with cognitive testing or performance, including specificities of cognitive assessment in dialysis patients or after kidney transplantation; and available tests for screening and observed cognitive patterns in CKD patients.
KW - chronic kidney disease
KW - clinical assessment
KW - cognitive impairment
KW - cognitive screening test
KW - comprehensive battery
UR - http://www.scopus.com/inward/record.url?scp=85123025429&partnerID=8YFLogxK
U2 - 10.1093/ndt/gfab262
DO - 10.1093/ndt/gfab262
M3 - Review article
C2 - 34718757
AN - SCOPUS:85123025429
SN - 0931-0509
VL - 37
SP - II23-II32
JO - Nephrology Dialysis Transplantation
JF - Nephrology Dialysis Transplantation
ER -